Browse Studies — Arctuva

Phase 3

A Phase 3, Open-label, Multicenter Continuation Trial to Evaluate the Long-term Safety and Efficacy of Mezagitamab Subcutaneous Injection in Adults With Chronic Primary Immune Thrombocytopenia

Primary immune thrombocytopenia (ITP) is a condition where the immune system mistakenly destroys platelets, which are cells that help stop bleeding. This leads…

Immune Thrombocytopenic Purpura (ITP)

Estimated

~$10 – $7,500

TakedaNCT06948318

Phase 3

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Mezagitamab Subcutaneous Injection in Participants With Chronic Primary Immune Thrombocytopenia

Primary immune thrombocytopenia (ITP) is a condition where the immune system mistakenly destroys platelets, which are cells that help stop bleeding. This leads…

Immune Thrombocytopenic Purpura (ITP)

Estimated

~$10 – $7,500

TakedaNCT06722235

Phase 1

A Phase 1/2 Dose Evaluation Trial of the Safety and Preliminary Efficacy of Anti CD19 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX112) in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease

This is a single-arm, open-label, multicenter, ascending dose Phase 1/2 trial evaluating the safety and preliminary efficacy of CTX112 or Zugocabtagene geleuce…

Warm Autoimmune Hemolytic Anemia (WAIHA)ITP - Immune ThrombocytopeniaWarm Autoimmune Hemolytic Anemia+1 more

Estimated

~$10 – $8,750

CRISPR Therapeutics AGNCT07549698

Phase 1

The Use of Dose Dense Rituximab for High Risk Patients With Newly Diagnosed Acute Immune Thrombocytopenic Purpura

The purpose of this study is to determine if a dose dense administration of Rituximab in newly diagnosed acute immune thrombocytopenic purpura (ITP) and determ…

Immune Thrombocytopenic Purpura

Estimated

~$10 – $6,250

New York Medical CollegeNCT04323748